<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173325</url>
  </required_header>
  <id_info>
    <org_study_id>GCC-20-009</org_study_id>
    <nct_id>NCT04173325</nct_id>
  </id_info>
  <brief_title>Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer</brief_title>
  <official_title>Phase I Feasibility and Safety Study of Nivolumab in Combination With Irinotecan in Relapsed or Refractory Small Cell Lung Cancer (SCLC) Followed by Maintenance Nivolumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the frequency of adverse events (side effects) in patients with
      relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan
      together followed by nivolumab maintenance. This study will test the safety of the study
      treatments when given together and see what effect (good or bad) it has on participants and
      their cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the frequency and severity of adverse events in patients with small cell lung cancer after receiving nivolumab plus irinotecan followed by nivolumab maintenance.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>CTCAE v.4.0. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Tumor response evaluation with RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>PFS as measured from start of therapy till disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>through study completion, an average of 1 year.</time_frame>
    <description>OS as measured from start of therapy till date of death or last follow up assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab and Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]</intervention_name>
    <description>PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.</description>
    <arm_group_label>Nivolumab and Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Injection [Camptosar]</intervention_name>
    <description>Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.</description>
    <arm_group_label>Nivolumab and Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed SCLC with known UGT1A genotype.

          -  Patients who have received at least 1 prior platinum-based chemotherapy.

          -  Life expectancy of 3 months or more.

          -  Measurable disease.

        Exclusion Criteria:

          -  Patients with UGT1A polymorphism.

          -  Currently receiving chemotherapy.

          -  Pregnant and nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagla A Karim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University Georgia Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Jenkins, MSN, RN</last_name>
    <phone>706-721-1206</phone>
    <email>kejenkins@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashlyn Stevenson, BSN, RN</last_name>
    <phone>706-721-0660</phone>
    <email>asstevenson@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgia Cancer Center at AU Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jenkins, MSN, RN</last_name>
      <phone>706-721-1206</phone>
      <email>kejenkins@augusta.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashlyn Stevenson, RN, BSN</last_name>
      <phone>706-721-0660</phone>
      <email>asstevenson@augusta.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nagla A Karim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Nagla Abdel Karim</investigator_full_name>
    <investigator_title>Professor, Hematology/Oncology, Director of Thoracic Oncology and Phase I Program</investigator_title>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Relapsed lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

